Mary Beth Boland, CVT

I wanted to again share our clinical trial for dogs with metastatic osteosarcoma. The Comparative Immunotherapy Program at the University of Pennsylvania School of Veterinary medicine is using Invariant Natural Killer T-Cells (iNKT cells) from healthy donor dogs to target metastatic disease in dogs with osteosarcoma.

The study is currently enrolling dogs who:
🩺Have a diagnosis of osteosarcoma
🩺Have previously undergone amputation and chemotherapy
🩺Now have evidence of metastatic disease in their lungs
🩺Have no other serious concurrent disease

For more information about enrollment please contact
Mary Beth Boland, CVT
📧 [email protected]
☎️215-898-5098
🛜https://veterinaryclinicaltrials.org/study/VCT24005853
*Please no Facebook DMs*

The newly founded PennVet Comparative Immunotherapy Program (CIP) is recruiting for a ground breaking clinical trial using CAR-iNKT cells to treat metastatic osteosarcoma. We are investigating the safety and efficacy of this new treatment option in dogs with disease that has now spread to their lungs. We are using a new type of immunotherapy made from the cells of healthy donor dogs to target and attack osteosarcoma cells.

At this time the study is pre-screening dogs who meet the following criteria:

🐶 Body weight of at least 40lbs
🐶 Previous diagnosis of osteosarcoma
🐶 Previous amputation of affected limb
🐶 Previous treatment with standard of care chemotherapy
🐶 Evidence of measurable metastatic disease in the lungs
🐶 No significate concurrent disease (cardiac, kidney, etc)
🐶 Ability to travel to the University of Pennsylvania School of Veterinary Medicine in Philadelphia, PA for all study visits.

This study is FULLY FUNDED by the National Cancer Institute. There is no cost to pet owners for any treatment related to the study.

For more information, please contact Mary Beth Boland, CVT at [email protected] or 215-898-5098

For more information on the PennVet CIP: https://www.vet.upenn.edu/research/research-programs/comparative-immunotherapy-program/

For more information on this clinical trial: https://veterinaryclinicaltrials.org/study/VCT24005853

To listen to Dr Nicola Mason, the founder of PennVet CIP talk about this clinical trial on the TriPawds Podcast: https://tripawds.com/2025/08/06/osteosarcoma-clinical-trial-with-dr-nicola-mason-on-tripawd-talk-130/

Dr Mason was recently featured in the Emmy Award nominated PBS documentary "Shelter Me: The Cancer Pioneers" Watch for free here: https://www.pbs.org/video/the-cancer-pioneers-jemhoc/

The PennVet Comparative Immunotherapy Program is now enrolling for a clinical trial to treat canine B-cell lymphoma using IL-18 armored CART-19 cells.

This is a fully funded study at no cost to the client.

Inclusion criteria:
🐶 Body weight of at least 10kg (22lbs)
🐶 Dogs with a cytological diagnosis of lymphoma
🐶 Dogs with stage II-V lymphoma with at least 2 involved peripheral lymph nodes that can be measured
🐶 Dogs who have not responded to standard of care chemotherapy (induction or rescue protocols) OR who have relapsed following standard of care chemotherapy and who’s owners have decided not to pursue rescue chemotherapy OR dogs with treatment naïve disease who’s owners have opted not to treat with chemotherapy
🐶 Dogs who have not received cytotoxic chemotherapy for at least 3 weeks
🐶 No significant co-morbidities
🐶 Expected survival time of at least 2 months at the time of enrollment.
🐶 Ability to attend all study visits at the University of Pennsylvania in Philadelphia, PA

Contact:
Mary Beth Boland, CVT
📨 [email protected]
📞 215-898-5098

*Please no Facebook DMs*

Welcome! I'll be utilizing this platform to share my thoughts on updates and advances in veterinary medicine. Looking forward to positive discussions and advancing the quality of care we provide.